AlphaGrep UK’s Bio-Rad Laboratories Class A BIO Stock Holding History

AlphaGrep UK’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-847	Closed	-$249K	–	763
2026 Q2	$249K	Buy	+847	New	+$240K	0.07%	588

Other funds holding BIO

First Eagle Investment Management New York $63.7B AUM 20.33% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Ariel Investments Chicago, Illinois $9.6B AUM 22.21% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $25.4B AUM 35.48% 1-Year Est. Return

Neuberger Berman Group New York $148B AUM 31.56% 1-Year Est. Return

AlphaGrep UK's BIO Position: Q3 2026 in Review

AlphaGrep UK sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2026, closing a stake of 847 shares — an estimated $249K sold.

AlphaGrep UK first reported a position in BIO in Q2 2026 and held it in 1 quarter. The position peaked at $249K in Q2 2026. 327 funds tracked by Wall St. Rank hold BIO as of Q3 2026.

AlphaGrep UK reported no remaining Bio-Rad Laboratories Class A position as of Q3 2026 after selling out during the quarter.
AlphaGrep UK sold 847 Bio-Rad Laboratories Class A shares in Q3 2026, an estimated $249K.
AlphaGrep UK first reported a position in Bio-Rad Laboratories Class A in Q2 2026 and held it in 1 quarter.
AlphaGrep UK's Bio-Rad Laboratories Class A position peaked at $249K in Q2 2026.
327 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2026.

Based on AlphaGrep UK's 13F filing for Q3 2026, filed 12 Nov 2026.